VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
A Phase 2 Study of VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama
-
-
California
-
Berkeley, California, United States, 94704
- Alta Bates Medical Center
-
Duarte, California, United States, 91010-3000
- City of Hope Comprehensive Cancer Center
-
Loma Linda, California, United States, 92354
- Loma Linda Cancer Research Institute
-
Los Angeles, California, United States, 90095
- UCLA School of Medicine
-
Palo Alto, California, United States, 94304
- Stanford University
-
-
Colorado
-
Denver, Colorado, United States, 80262
- University of Colorado Cancer
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University Medical Center Lombardi Cancer Center
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center & Research Institute
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- The Emory Clinic
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University Of Chicago Medical Center
-
Chicago, Illinois, United States, 60612
- The Rush Cancer Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Cancer Center
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospital Division
-
-
Minnesota
-
Robbinsdale, Minnesota, United States, 55422
- North Memorial Hospital
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Onc/Hem Associates of Kansas City
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New York
-
New York, New York, United States, 10003
- Beth Israel Medical Center
-
New York, New York, United States, 10021
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10019
- St Lukes-Roosevelt Hospital
-
New York, New York, United States, 10021
- New York Hospital Cornell Medical Center
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest, University health Sciences/Comprehensive Cancer Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- Cancer Care Associates
-
Tulsa, Oklahoma, United States, 74136
- Cancer Care Associates
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Cancer Center
-
Pittsburgh, Pennsylvania, United States, 15224
- Western Pennsylvania Hospital
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University
-
Nashville, Tennessee, United States
- Sarah Cannon Cancer Center
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University Hospital-Madison Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- 18 years of age or older
- Confirmed diagnosis of mantle cell lymphoma
- Documented relapse or progressive disease following 1 or 2 prior lines of anti-cancer therapy. At least one of those regimens must have included an anthracycline or mitoxantrone. Relapsed or progressive disease, since last therapy must be documented by new lesions or objective evidence of the progression of existing lesions.
- At least 1 measurable or evaluable site of disease
- Voluntary consent
Exclusion Criteria
- Previous treatment with VELCADE
- Any experimental or anti-cancer therapy within 3 weeks before the first dose of study drug
- Radiation therapy within 3 weeks before the first dose of study drug
- Major surgery with 2 weeks before the first dose of study drug
- Rituximab, Campath, or other unconjugated therapeutic antibody within 4 weeks before the first dose of study drug
- Radioimmunotherapy or other toxin immunoconjugates such as Zevalin or Bexxar within 10 weeks before the first dose of study drug
- History of allergic reactions to boron or mannitol compounds
- Diagnosed or treated for another malignancy other than mantle cell lymphoma with 5 years before the first dose of study drug
- Active systemic infection requiring treatment
- Women patients must not be pregnant or breast-feeding, confirmed through pregnancy test obtained during screening (this test is not required for women who are post-menopausal or surgically sterile)
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study
- Concurrent treatment with another investigational drug or participation in non-treatment studies is not allowed if it interferes with participation in this clinical study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- M34103-053
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.